TB drug dosing under the microscope: could standard doses be off?
NCT ID NCT06054334
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study examined whether the standard dose of isoniazid, a key tuberculosis drug, is right for all adults. Researchers measured drug levels in 112 patients to see if some were getting too much or too little. The goal was to understand how individual differences in drug processing might affect treatment safety and success.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Amiens Picardie
Amiens, Picardie, 80054, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune profiling unlock the hidden stages of tuberculosis?
- Could inhaled TB drugs curb the spread of Drug-Resistant tuberculosis?
- Can new tests predict who will develop active TB?
- Could a 3-Month TB cocktail replace the standard 6-Month regimen?
- Could a simple blood test ensure the right TB dose for kids?
- Community-Driven TB screening aims to reach vulnerable immigrants